×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR Newswire
SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous dosing successfully completed a 28-day GLP toxicity study and remains...
2 weeks ago
Spyre Therapeutics Announces $180 Million Private Placement
PR Newswire
PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of...
2 months ago
Spyre Therapeutics Announces Grants of Inducement Awards | | news-journal.com
Longview News-Journal
WALTHAM, Mass., May 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage...
3 weeks ago
Spyre Therapeutics: Q1 Earnings Snapshot
Milford Mirror
WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Spyre Therapeutics, Inc. (SYRE) on...
2 weeks ago
Spyre Therapeutics Expands Portfolio and Strengthens Leadership - TipRanks.com
Tipranks
The latest update is out from Spyre Therapeutics (SYRE). Spyre Therapeutics, Inc. has secured a significant deal with Paragon Therapeutics, granting them...
1 week ago
Spyre Therapeutics names Sandra Milligan to board By Investing.com
Investing.com
WALTHAM, Mass. - Spyre Therapeutics, Inc. (NASDAQ: SYRE), a biotechnology company focusing on the development of therapies for Inflammatory...
1 week ago
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of “Buy” by Analysts
Defense World
Read Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of “Buy” by Analysts at Defense World.
6 days ago
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5.5%
MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) shares dropped 5.5% during mid-day trading on Thursday . The company traded as low...
2 days ago
Spyre Therapeutics (SYRE) Price Target Increased by 5.00% to 42.84
MSN
The average one-year price target for Spyre Therapeutics (NasdaqGS:SYRE) has been revised to 42.84 / share. This is an increase of 5.00% from the prior...
1 week ago
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
PR Newswire
PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing...
1 week ago